BiotechTube

Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Sedation in Non-intubated Diagnostic and Therapeutic Procedures

Conditions

Sedation in Non-intubated Diagnostic and Therapeutic Procedures

Trial Timeline

Jan 1, 2024 → Mar 1, 2024

NCT ID
NCT06216444

About Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection

Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection is a approved stage product being developed by Jiangsu Hengrui Medicine for Sedation in Non-intubated Diagnostic and Therapeutic Procedures. The current trial status is unknown. This product is registered under clinical trial identifier NCT06216444. Target conditions include Sedation in Non-intubated Diagnostic and Therapeutic Procedures.

What happened to similar drugs?

8 of 20 similar drugs in Sedation in Non-intubated Diagnostic and Therapeutic Procedures were approved

Approved (8) Terminated (2) Active (12)
✅Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + FentanylEisaiApproved
✅fospropofol disodium Subgroup 1 Lower Dose + fospropofol disodium Subgroup 1 Approved Dose + fospropofol disodium Subgroup 2 Lower Dose + fospropofol disodium Subgroup 2 Approved Dose + fospropofol disodium Subgroup 3 Lower Dose + fospropofol disodium Subgroup 3 Approved DoseEisaiApproved
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
✅Dexmedetomidine load + Ketamine load + Midazolam load + Fentanyl load + Dexmedetomidine maintenance + Ketamine maintenance + Midazolam demand + Fentanyl demand + Benadryl demandPfizerApproved
✅Dexmedetomidine + PropofolPfizerApproved
✅dexmedetomidine + propofolPfizerApproved
✅DexmedetomidinePfizerApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06216444ApprovedUNKNOWN

Competing Products

20 competing products in Sedation in Non-intubated Diagnostic and Therapeutic Procedures

See all competitors
ProductCompanyStageHype Score
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCIEisaiPhase 3
40
Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + FentanylEisaiApproved
35
fospropofol disodium Subgroup 1 Lower Dose + fospropofol disodium Subgroup 1 Approved Dose + fospropofol disodium Subgroup 2 Lower Dose + fospropofol disodium Subgroup 2 Approved Dose + fospropofol disodium Subgroup 3 Lower Dose + fospropofol disodium Subgroup 3 Approved DoseEisaiApproved
43
AQUAVAN® (fospropofol disodium) InjectionEisaiPhase 2/3
38
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
35
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Remimazolam TosilateJiangsu Hengrui MedicinePhase 1/2
32
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
26
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
40
Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion InjectionJiangsu Hengrui MedicinePhase 3
40
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
40
SHR0302 Base Gel + SHR0302 Base Gel PlaceboJiangsu Hengrui MedicinePhase 1
29
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
26
Remimazolam Tosilate for injection + Propofol InjectionJiangsu Hengrui MedicinePhase 2/3
45
Dexmedetomidine hydrochloride nasal spray + Dexmedetomidine hydrochloride nasal spray blank preparation.Jiangsu Hengrui MedicinePhase 1
29
Intranasal Dexmedetomidine + Intravenous Dexmedetomidine + Intranasal Placebo + Intravenous PlaceboJiangsu Hengrui MedicinePhase 1
25
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 2
35
dexmedetomidine nasal spray + dexmedetomidine hydrochloride nasal spray blank preparationJiangsu Hengrui MedicinePhase 2/3
34
Remimazolam Tosilate + Propofol Injection.Jiangsu Hengrui MedicinePhase 2
35